spacer
home > ebr > winter 2003 > the progress of clinical trials
PUBLICATIONS
European Biopharmaceutical Review

The Progress of Clinical Trials

In the search to understand, prevent and treat disease, clinical trials involving healthy volunteers and patients play an essential role. How and why such trials are conducted needs to be understood by the public - as well as by key decision-makers - so that clinical research in the UK receives the focus and attention necessary for it to be successful. Nearly a quarter of the world's top 100 medicines were developed in the UK, making it a leading centre for clinical trials. But clinical studies are increasingly conducted around the world so that greater numbers of patients and different ethnicities can be included in a study.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Professor Trevor Jones, Director General at ABPI

Professor Trevor Jones is Director General of The Association of the British Pharmaceutical Industry, directing all activities relating to the UK pharmaceutical industry, including government relations, on behalf of 80 national and international pharmaceutical companies. From 1987 to 1994, Professor Jones was a main Board Director of Wellcome plc, the UK-based pharmaceuticals company, where he was responsible for R&D, including the development of Zovirax, AZT, Malarone, Lamictal and Tracrium. He was awarded the CBE in the 2003 New Year's Honours List.

spacer
Professor Trevor Jones
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

Case Study: Cmed’s Mobile Data Management Solution

Cmed Clinical Services

The trial presented to Cmed was a randomized, double blinded, placebo and active controlled study to evaluate the cardiac safety of multiple doses of [study drug] in health volunteers. The pharmaceutical company, who were into the second year of development of a potential blockbuster compound for the treatment of chronic myelogenous leukaemia (CML), were requested by the FDA to design a trial to provide information on the cardiac safety of different dose levels of the study drug in healthy adult volunteers. The primary objective of the study was specifically to find the maximum tolerated dose before QTc levels became unsafe. All development of the compound was put on hold until the results of this study were submitted to the FDA and approval granted for the compound to progress into full development.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement